TTANGO (Test, Treat ANd Go) is a randomised trial that aims to measure the effectiveness, cost-effectiveness and cultural and operational acceptability of point-of-care testing for chlamydia and gonorrhoea infections in remote Aboriginal communities. The trial utilises the GeneXpert CT/NG (Cepheid), a new point-of-care testing device that employs nucleic acid amplification technology to accurately detect chlamydia and gonorrhoea.
The Kirby Institute (University of NSW) were awarded an NHMRC grant to fund the TTANGO clinical trial. The Centre’s Director, Professor Shephard is a Chief Investigator on this project.
The trial commenced mid 2011 in 12 remote Aboriginal communities across Australia.
For more information go to the Kirby Institute website.